XML 126 R109.htm IDEA: XBRL DOCUMENT v3.25.3
Supplemental Financial Information - Schedule of Supplemental Statement of Cash Flows (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Cash flows from operating activities          
Net income $ 112.5 $ 615.7 $ 599.2 $ 863.8  
Adjustments to reconcile net income to net cash flows from operating activities:          
Depreciation and amortization     143.1 137.0  
Equity-based compensation 90.7 121.6 287.1 355.1  
Non-cash performance allocations and incentive fees     13.1 (387.9)  
Non-cash principal investment (income) loss     (50.2) (188.4)  
Other non-cash amounts     35.9 15.8  
Purchases of investments     (251.1) (213.8)  
Proceeds from the sale of investments     664.0 333.3  
Payments of contingent consideration     (2.7) (4.0)  
Changes in deferred taxes, net     (67.5) 98.3  
Change in due from affiliates and other receivables     (8.7) (40.1)  
Change in deposits and other     (25.4) (5.4)  
Change in accounts payable, accrued expenses and other liabilities     37.8 15.4  
Change in accrued compensation and benefits     (61.4) (170.8)  
Change in due to affiliates     25.1 (0.9)  
Change in lease right-of-use assets and lease liabilities     (9.7) (5.4)  
Change in deferred revenue     226.7 238.1  
Net cash used in operating activities     (2,080.4) (406.7)  
Cash flows from investing activities          
Purchases of corporate treasury investments     0.0 (5.0)  
Proceeds from corporate treasury investments     0.0 5.1  
Purchases of fixed assets, net     (57.4) (51.0)  
Net cash used in investing activities     (57.4) (50.9)  
Cash flows from financing activities          
Borrowings under credit facilities     0.0 10.4  
Repayments under credit facilities     0.0 (10.4)  
Issuance of 5.05% senior notes due 2035, net of financing costs     792.9 0.0  
Payments on CLO borrowings     (52.0) (73.3)  
Proceeds from CLO borrowings, net of financing costs     64.8 0.5  
Dividends to common stockholders     (379.2) (377.8)  
Payment of deferred consideration for Carlyle Holdings units     0.0 (68.8)  
Contributions from non-controlling interest holders     599.1 219.2  
Distributions to non-controlling interest holders     (308.1) (73.0)  
Common shares repurchased and net share settlement of equity-based awards     (482.8) (478.8)  
Change in due to/from affiliates financing activities     25.6 2.2  
Net cash provided by financing activities     3,015.4 370.7  
Effect of foreign exchange rate changes     82.3 23.7  
Increase (decrease) in cash, cash equivalents and restricted cash     959.9 (63.2)  
Cash, cash equivalents and restricted cash, beginning of period     1,266.5 1,442.1  
Cash, cash equivalents and restricted cash, end of period 2,226.4 1,378.9 2,226.4 1,378.9  
Reconciliation of cash, cash equivalents and restricted cash, end of period:          
Cash and cash equivalents 2,221.7 1,376.8 2,221.7 1,376.8 $ 1,266.0
Restricted cash 4.7 2.1 4.7 2.1 0.5
Total cash, cash equivalents and restricted cash, end of period 2,226.4 1,378.9 2,226.4 1,378.9 1,266.5
Cash and cash equivalents held at Consolidated Funds $ 1,037.3 488.5 $ 1,037.3 488.5 830.4
5.050% Senior Notes Due 9/19/2035          
Reconciliation of cash, cash equivalents and restricted cash, end of period:          
Interest rate (percent) 5.05%   5.05%    
Consolidated Operating Entities          
Cash flows from operating activities          
Net income     $ 486.0 847.1  
Adjustments to reconcile net income to net cash flows from operating activities:          
Depreciation and amortization     143.1 137.0  
Equity-based compensation     287.1 355.1  
Non-cash performance allocations and incentive fees     2.7 (389.1)  
Non-cash principal investment (income) loss     (32.5) (182.0)  
Other non-cash amounts     35.9 15.8  
Purchases of investments     (872.6) (479.4)  
Proceeds from the sale of investments     807.6 435.7  
Payments of contingent consideration     (2.7) (4.0)  
Changes in deferred taxes, net     (67.5) 98.3  
Change in due from affiliates and other receivables     (8.1) (38.2)  
Change in deposits and other     (25.4) (5.4)  
Change in accounts payable, accrued expenses and other liabilities     37.8 15.4  
Change in accrued compensation and benefits     (61.4) (170.8)  
Change in due to affiliates     25.1 (0.9)  
Change in lease right-of-use assets and lease liabilities     (9.7) (5.4)  
Change in deferred revenue     226.7 238.1  
Net cash used in operating activities     972.1 867.3  
Cash flows from investing activities          
Purchases of corporate treasury investments     0.0 (5.0)  
Proceeds from corporate treasury investments     0.0 5.1  
Purchases of fixed assets, net     (57.4) (51.0)  
Net cash used in investing activities     (57.4) (50.9)  
Cash flows from financing activities          
Borrowings under credit facilities     0.0 10.4  
Repayments under credit facilities     0.0 (10.4)  
Payments on CLO borrowings     (52.0) (73.3)  
Proceeds from CLO borrowings, net of financing costs     64.8 0.5  
Dividends to common stockholders     (379.2) (377.8)  
Payment of deferred consideration for Carlyle Holdings units     0.0 (68.8)  
Contributions from non-controlling interest holders     116.9 155.2  
Distributions to non-controlling interest holders     (83.9) (58.9)  
Common shares repurchased and net share settlement of equity-based awards     (482.8) (478.8)  
Change in due to/from affiliates financing activities     29.4 13.3  
Net cash provided by financing activities     6.1 (888.6)  
Effect of foreign exchange rate changes     39.1 9.0  
Increase (decrease) in cash, cash equivalents and restricted cash     959.9 (63.2)  
Cash, cash equivalents and restricted cash, beginning of period     1,266.5 1,442.1  
Cash, cash equivalents and restricted cash, end of period $ 2,226.4 1,378.9 2,226.4 1,378.9  
Reconciliation of cash, cash equivalents and restricted cash, end of period:          
Cash and cash equivalents 2,221.7 1,376.8 2,221.7 1,376.8  
Restricted cash 4.7 2.1 4.7 2.1  
Total cash, cash equivalents and restricted cash, end of period 2,226.4 1,378.9 2,226.4 1,378.9 $ 1,266.5
Cash and cash equivalents held at Consolidated Funds $ 1,037.3 $ 488.5 $ 1,037.3 $ 488.5